Target intelligence / Profile preview

Methylcytosine dioxygenase TET3 (TET3) (TET3)

Target
TET3
Molecular classification
Enzyme [1, 2], Dioxygenase [1, 11], Fe(II)/2-oxoglutarate-dependent dioxygenase [1, 11], Epigenetic regulator [1, 10], Eraser [11]
01

Overview

Methylcytosine dioxygenase TET3 (TET3) is a member of the Ten-eleven translocation family of enzymes that play a central role in epigenetic regulation through active DNA demethylation [1, 11]. It functions as a Fe(II)- and 2-oxoglutarate-dependent dioxygenase, sequentially oxidizing 5-methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) [1, 5, 11]. TET3 is specifically critical for zygotic paternal DNA reprogramming and is induced during the differentiation of embryonic stem cells to regulate lineage specification and neuronal plasticity [12, 16]. In clinical contexts, TET3 dysregulation is associated with numerous pathologies: its inactivation or deficiency causes Beck-Fahrner syndrome (a neurodevelopmental disorder), while its overexpression in specific macrophage populations drives chronic inflammation in conditions like metabolic dysfunction-associated steatohepatitis (MASH) and endometriosis [10, 15, 19]. Though direct therapeutic targeting is in early stages, Vitamin C is a known cofactor that enhances its activity, and experimental small-molecule inhibitors and degraders are being developed to modulate its epigenetic function in cancer and inflammatory diseases [5, 6, 10, 17].

Other names
Ten-eleven translocation 3Ten-eleven translocation methylcytosine dioxygenase 3TET3 methylcytosine dioxygenaseCXXC-type zinc finger protein 10
02

Mechanism of action

TET3 activity is modulated by cofactors like Vitamin C that enhance its catalytic oxidation of 5-methylcytosine, or by small-molecule inhibitors and degraders that prevent its association with target promoters or reduce its protein levels to suppress pathogenic gene expression and global DNA demethylation [5, 6, 10, 17].

03

Biological functions

Active DNA demethylation [1, 11]Epigenetic regulation [1, 12]Zygotic DNA reprogramming [12, 16]Neuronal plasticity and homeostatic synaptic plasticity [16]Gene expression regulation during lineage specification [10, 12]Oxidation of 5-methylcytosine to 5-hydroxymethylcytosine [1, 11]
04

Disease associations

Cancer (e.g., Head and neck carcinoma, Triple-negative breast cancer, NSCLC) [6, 8, 10, 17, 18]Neurodevelopmental disorder (Beck-Fahrner syndrome/BEFAHRS) [15, 19]Chronic inflammation (e.g., Endometriosis) [10, 11]Metabolic dysfunction-associated steatohepatitis (MASH) [10]Liver fibrosis [10]Autoimmune disease (Systemic lupus erythematosus) [14]Psychiatric and memory-related disorders [1, 16]
05

Safety considerations

Perinatal lethality (observed in knockout models) [12, 13, 15]Global epigenetic instability and genome-wide hypermethylation [1, 15, 19]Neurodevelopmental abnormalities (e.g., craniofacial and motor deficits) [15, 19]Potential risk of chromosomal instability and tumor progression upon inactivation [18]
06

Interacting drugs

Vitamin C (Ascorbic acid) [1, 17]

4 more in the full profile.

07

Biomarkers

5-hydroxymethylcytosine (5hmC) levels [15, 17]DNA hypermethylation episignature [15, 19]TET3 protein expression in serum or tissue [10, 18]Promoter methylation status of TET3 [18]

Beyond the preview

Go deeper on Methylcytosine dioxygenase TET3 (TET3) (TET3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Methylcytosine dioxygenase TET3 (TET3) (TET3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call